Bradley Block, MD
Family Medicine · Oviedo, FLNPI 1205819307
Payments from drug & device makers
Across 1,397 payments — averaging $2177.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.8M
- Novo Nordisk AS$633K
- Sanofi US Services Inc.$406K
- Pfizer$117K
- Bayer$30K
- Eisai Inc.$17K
- plus $38K from 34 others
Across 9 payments — averaging $4223.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$38K
What the payments were for
- Consulting fees$8,46384%
- Food & beverage$1,58516%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 30 | $1,799,931 |
| Novo Nordisk AS | 1,149 | $632,990 |
| Sanofi US Services Inc. | 42 | $406,236 |
| Pfizer | 49 | $117,312 |
| Bayer | 24 | $29,576 |
| Eisai Inc. | 12 | $17,201 |
| Myovant Sciences Inc. | 2 | $10,357 |
| Pacira Therapeutics, Inc. | 1 | $10,135 |
| Boehringer Ingelheim | 6 | $5,372 |
| Novo Nordisk | 6 | $4,467 |
| Lilly USA, LLC | 8 | $3,012 |
| AMAG Pharmaceuticals, Inc. | 1 | $2,650 |
| Jazz Pharmaceuticals Inc. | 2 | $840 |
| AbbVie(2 entities) | 13 | $228 |
| GSK | 8 | $218 |
| AstraZeneca | 7 | $110 |
| Medtronic | 1 | $84 |
| Merck | 6 | $84 |
| Amgen | 3 | $48 |
| Johnson & Johnson(2 entities) | 3 | $43 |
| Novartis | 2 | $39 |
| Renalytix AI, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Photonicare Inc | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Abbott | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Biogen | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Vistapharm, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$113
How this compares
$3,041,361 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 103 | $108,872 |
| JardianceEmpagliflozin | 67 | $66,483 |
| Repatha SureclickEvolocumab | 37 | $30,302 |
| OzempicSemaglutide | 33 | $29,527 |
| EliquisApixaban | 27 | $28,881 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,013 |
| JanuviaSitagliptin Phosphate | 18 | $19,650 |
| XareltoRivaroxaban | 20 | $17,767 |
| FarxigaDapagliflozin Propanediol | 18 | $13,082 |
| Praluent PenAlirocumab | 13 | $12,352 |
| EntrestoSacubitril/Valsartan | 12 | $12,158 |
| Duloxetine Hcl | 110 | $4,153 |
| Famotidine | 135 | $4,038 |
| Rosuvastatin Calcium | 279 | $3,746 |
| Ezetimibe | 178 | $3,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $3,012 | $108,872103 claims |
| Boehringer IngelheimJardiance | $5,372 | $66,48367 claims |
| Novo NordiskOzempic | $4,467 | $29,52733 claims |
| PfizerEliquis | $117,312 | $28,88127 claims |
| GSKTrelegy Ellipta | $218 | $21,01328 claims |
| MerckJanuvia | $84 | $19,65018 claims |
| Johnson & JohnsonXarelto | $43 | $17,76720 claims |
| AstraZenecaFarxiga | $110 | $13,08218 claims |
| NovartisEntresto | $39 | $12,15812 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $18 | $1,93312 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $1,718193 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Oviedo
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.